Why Packaging Design Should Be Involved Earlier in Drug Development
From a regulatory and patient-use perspective, packaging is inseparable from the drug it contains. It protects the product, maintains sterility, ensures stability, enables proper dosing, and supports safe use. Decisions around materials, formats, and sealing methods can directly influence:
- Moisture, oxygen, and light protection
- Patient compliance by communicating how and when a therapy needs to be administered
- Compatibility with sensitive formulations
- Ease of use for patients and healthcare providers
- Artwork and branding on the package
Early Collaboration Reduces Development Risk
Late-stage packaging changes can create additional costs. A minor adjustment can trigger additional testing, revalidation, or even clinical impact assessments. By involving packaging experts early, teams can:
- Identify potential material incompatibilities before testing begins
- Design packaging concepts that align with anticipated regulatory requirements
- Avoid late-stage surprises that delay submissions or launch timelines
Improving Patient-Centric Design from the Start
Patient-centricity is no longer optional. Stakeholders expect packaging that is intuitive, accessible, and safe. Early packaging involvement allows teams to consider:
- Ease of opening for patients with limited dexterity
- Clear labeling and instructions for at-home use
- Child-resistant or senior-friendly features
- Dosing accuracy and error prevention
Ultimately, involving packaging design earlier in drug development leads to better outcomes: fewer delays, lower risk, and a more robust final product. Packaging is not just a container—it’s a critical interface between the therapy and the patient. Organizations that embrace this mindset position themselves to move faster and deliver safer, more user-friendly therapies to market.
Sources